E.-M. Grischke - Dept. für Frauengesundheit, Universitätsklinikum Tübingen

基本信息

浏览量：39

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 53 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

LBA24 Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology

O. Gluz, M. Christgen,C. zu Eulenburg, U.A. Nitz, S. Kummel, M. Braun, B. Aktas, K. Luedtke-Heckenkamp, H. Forstbauer,E-M. Grischke, C. Schumacher, R.F.L. Baehner,

Annals of Oncology (2023): S1262-S1263

引用0浏览0引用

18P A translational project of the WSG-ADAPT-TN trial demonstrates immunomodulatory and anti-viral defense gene networks predicting pathological complete response (pCR) and survival after de-escalated neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC)

M. Graeser, N. Harbeck,O. Gluz, U.A. Nitz,M. Christgen, S. Kuemmel,E-M. Grischke,H. Forstbauer,M. Braun, M. Warm, J.C. Hackmann,C. Uleer,

ESMO Openno. 1 (2023): 101242-101242

引用0浏览0引用

Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772]

U A Nitz,O Gluz,M Christgen,E-M Grischke,D Augustin,S Kuemmel,M Braun, J Potenberg, A Kohls, K Krauss, A Stefek,C Schumacher,

Annals of oncology : official journal of the European Society for Medical Oncology（2022）

引用1浏览0WOS引用

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

Cornelia Kolberg-Liedtke,Friedrich Feuerhake,Madlen Garke,Matthias Christgen,Ronald Kates,Eva Maria Grischke,Helmut Forstbauer,Michael Braun,Mathias Warm,John Hackmann,Christoph Uleer,Bahriye Aktas,

Breast Cancer Res（2022）

引用4浏览0WOS引用

Predictive Impact Of Biomarkers On Pcr And Survival After De-Escalated Neoadjuvant T-Dm1 With Or Without Endocrine Therapy (Et) Vs. Trastuzumab+Et In Her2+/Hr+ Early Breast Cancer: Wsg Adapt Tp Trial

N. Harbeck, U. Nitz, M. Christgen,S. Kuemmel,M. Braun, C. M. Biehl,C. Schumacher, W. Malter,B. Aktas, H. Forstbauer, J. Tio,E-M. Grischke,

ANNALS OF ONCOLOGY（2021）

引用6浏览0引用

Pathologische Komplettremissionsrate und Überleben von Patientinnen mit BRCA-assoziiertem triple-negativen Brustkrebs nach 12 Wochen anthrazyklinfreier neoadjuvanter Chemotherapie: Ergebnisse der WSG-ADAPT TN Studie (NCT01815242)

LK Richters,O Gluz, N Weber-Lassalle, M Christgen, H Haverkamp,S Kuemmel, M Kayali, R Kates,E-M Grischke, M Braun, M Warm, R Wuerstlein,

Senologie - Zeitschrift für Mammadiagnostik und -therapieWissenschaftliche Abstracts zur 40. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. (DGS) Interdisziplinär. Kommunikativ. Digital (2021)

引用0浏览0引用

LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial